Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There is no reverse supply on the table. A minimum bid price of$1 is not a requirement of other requirements are met. Those requirements have been met.
Why would you ever invest in a company that would have anything to do with that dirtbag, Trump?
So what. He's a scientist, not CEO material. It's a good thing. By the way, there was an explanation. He wants to devote his time to AI although he'll still be consulting for KNW.
The reason why RKLY sports such a low market cap is that it only has 4 mil. in cash and is hemorrhaging money. They'll need to dilute soon to raise enough cash to continue operations. It's actually a very dicey situation.
Most ridiculous stock on the DAQ. What the hell is their business plan? Get out while you still can.
Why invest in a company that has no future? Come on people you're better than that.
Our patience will soon pay off. Congratulations to all who held through thick and thin.
KNOW will be uplisting to the NYSE per their latest release.
Class 1 device.
Time to clean up the misinformation being proffered by a few posters on this board.
From KNWN management on their discord channel:
Sorry for the delay. First of all, thanks for all the contributions. Second, we continue to test daily. For confidentiality reasons, we can't share details on the tests. Any material event will be communicated through press release and our social medial channels, including our newsletter. Lastly, it is time to start focusing on what happens once the internal trials are completed. We have been preparing for that, which includes refining the regulatory strategy, building the package of documents for pre-sub meeting, conducting 3rd party tests that prove compliance to safety requirements, and the list goes on and on. Rest assured, the team has been busy.
Slunj- when did they extend the deadline for their IRB study? Thanks in advance.
What deadline was missed? Please provide a link.
You don't understand how long it takes to get a medical device from concept to approval. The average time is 5-7 years. You need to chill out.
KNWN was started at Dawson James with a price target of $7
Wall Street doesn't like RKLY.
KNWN has a cash runway to the end of 2023. Great news-no dilution needed in the near future.
One reason for the market cap discrepancy is that RKLY has 113 million in cash.
KNOW's technology is indisputably superior to RKLY's. KNOW will have the first FDA-approved CGM on the market.
Touche. Thank you for bringing some real knowledge and insight to the board. All the endless conjecture gets quite boring.
LexaGene Starts the Year with Additional MiQLab Sales
BEVERLY, Mass. USA – January 3, 2022 – LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, is pleased to announce three additional purchase orders for MiQLab™ Systems from veterinary clinics in Michigan, Minnesota, and New York.
Julie Griggs, LexaGene’s Global Director of Sales, stated, “My team is diligently engaged with numerous veterinary practices, both private and corporate. Many of the veterinarians we have spoken to share our excitement over the value of in-clinic PCR testing and the capabilities that the MiQLab System can provide to their practices. It is gratifying to welcome 2022 with a strong start and continue our momentum as we work on closing additional sales.”
Dr. Jack Regan, LexaGene’s Founder and CEO said, “I’m pleased that we are making headway in the veterinary diagnostics marketplace. By acquiring MiQLab Systems, veterinary practices are setting themselves apart from their competition, as this technology allows them to elevate the standard of care they provide to companion animals. We look forward to educating veterinary practices in the coming year, regarding the importance of in-clinic PCR testing, and aim to revolutionize veterinary diagnostics through the sale of MiQLab Systems. No longer should veterinary practices empirically diagnosis our companion animals or send samples off to labs only to wait days or weeks for results when they can have a treatment plan in a fraction of the time.”
LexaGene is participating in the upcoming Veterinary Meeting and Expo (VMX) in Orlando, Florida, where more than 6,500 veterinarians, veterinary technicians, and practice managers will gather mid-January. On Sunday, January 16th, Dr. Jack Regan will be a presenter at the conference. Participants can attend his presentation entitled, “In-Clinic PCR Testing for Pathogen and Resistance Detection,” at 9:00 a.m. in the VMX Learning Theater.
Tax-loss selling to close out 2021. This will fly in the new year.
Rmmachio, Don't bother Ron... They are further along with the path to FDA clearance and RKLY does not possess the accuracy for FDA clearance. That's all.
Rmacchio, I am not a paid member of ihub so cannot converse with you privately. Is there another way to have private communication? I have some info to share with you- from a source I cannot mention publicly, that you will be very interested in hearing.
KNWN has made a lot of progress in the last six months. Why are you being such a Debbie Downer? I believe the best way forward for KNWN is to sell their CGM RFID application to the highest bidder. That would net them a tidy sum.
Potential suiters;
Samsung, Google, Fitbit... the list goes on.
NEWS! Finally unequivocal validation.
https://lexagene.com/release/2021/multiple-miqlab-sales/
GREAT NEWS. They're going for the whole enchilada!
LexaGene Intends to Pursue Full Panel Pathogen Testing through the FDA
November 24, 2021 16:00 ET | Source: LexaGene Holdings Inc
...
BEVERLY, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, today announced it intends to pursue both 510k clearance and CLIA-waiver from the FDA to utilize the full potential of the MiQLab System™ for syndromic testing at the point of care.
Syndromic testing allows medical providers to simultaneously test patient specimens for multiple pathogens that produce overlapping signs and symptoms. MiQLab’s broad multiplexing provides this capability and also allows for testing other clinically important markers such as antimicrobial resistance genes. Antimicrobial resistance is widely considered to be the next global pandemic.1 Scientists estimate that drug resistant pathogens will kill ~10 million people per year by the year 2050.2
Dr. Jack Regan, LexaGene’s Founder and CEO stated, “One of the hardest challenges in medicine is to rapidly identify, at the point-of-care, the exact cause of complex and difficult to treat infections.3 We’ve developed the MiQLab to tackle this challenging problem. It is capable of processing sample types that traditionally inhibit PCR (e.g., urine and fecal samples) and screens for up to 27 targets including drug resistance markers so it can be used in the fight against superbugs. We believe the MiQLab will be on the forefront of helping clinicians accurately diagnose and treat their patients at the point of care so that a pandemic caused by antimicrobial resistant pathogens can be avoided. Similarly, syndromic panels like respiratory or gastrointestinal panels will enable clinicians to more rapidly and conveniently diagnose infectious diseases, enabling earlier treatment and prevention.”
The Company has been steadily working to meet FDA requirements for human clinical diagnostics. The progress we have made during the pursuit of EUA for COVID-19 testing has brought the Company closer toward meeting the more extensive requirements of the traditional premarket review pathway, which will be required for the Company to offer broad panel pathogen testing at the point of care. The FDA recently provided industry-wide guidance4 and based on this guidance and direct communications with the agency, the Company has decided it will no longer pursue an EUA application for COVID-19, but instead pursue 510k and CLIA-waiver for broad-panel pathogen testing, thereby allowing the Company to focus on providing the MiQLab technology for its intended use of syndromic testing at the point of care.
LexaGene’s MiQLab system is unique in that it is a flow-through PCR system. To LexaGene’s knowledge, the FDA has never received an application for a flow-through PCR system for use in human clinical diagnostics. Until the FDA grants LexaGene’s system authorization for human clinical diagnostics, all work using LexaGene instruments is classified as Research Use Only.
The Company continues to sell its technology into veterinary hospitals, bio-pharmaceutical manufacturers, and other open-access markets.
bid 2.98 ask 3
I signed up to be notified when the particle bulb would be available to order. I posed as an owner of several restaurants, which perhaps gives greater credibility to their response. Time will tell.
KNWN will begin delivering the particle bulb towards the end of this summer.
Who would invest 14 million in KNWN if they weren't certain that something good is in the works?
Don't listen to the boobirds. Just read the previous post.
30 MAR CAN KNOW LAB DELIVER ON THE PROMISE OF ITS “DISRUPTIVE TECHNOLOGY”?
Posted at 10:46h in Biotechnology by admin 0 Comments
10Likes
Share
Know Labs, Inc. (OTCQB: KNWN) formerly known as Visualant, is a premier non-invasive medical diagnostics company that is leveraging its proprietary electromagnetic energy technology platforms, namely ChromaID and Bio-RFID technologies, to capture the unique molecular signature of any substance or material.
The Company shared preliminary study results from Texas Biomedical Research Institute (Texas Biomed) that demonstrate Particle bulb’s potential to inactivate SARS-CoV-2, which is responsible for the ongoing COVID-19 pandemic. Furthermore, the Particle bulb is also effective against bacteria and germs such as E. Coli, Salmonella, and Staphylococcus.
Phil Bosua, CEO of Know Labs, commented,
“We were very pleased to work with Texas Biomed because of their reputation as a global leader in eradicating infectious diseases and we’re really excited by these results.”
Particle is a disinfecting light bulb that can simultaneously illuminate and disinfect, and comes with a smart sensor. The bulb is safe for kids, pets and plants as its smart sensor deactivates UV when an individual is in the vicinity, and can be used in existing standard light sockets. The bulb’s gentle UV is 9,000x safer than traditional UV-C disinfecting products and confirms to the safety standards set by International Commission on Non-Ionizing Radiation Protection (ICNIRP) as per the Company.
The Company expects to start shipping the bulbs in the summer of 2021 and is targeting a wide array of settings such as Home, Restaurants, Hospitality, Workplaces, Schools and Universities as potential customers. Particle is also planning to offer commercial lighting options that can be customized to suit specific business requirements.
Know Labs, Inc. (OTCQB: KNWN)
Market Cap: $87.06M; Current Share Price: 3.31 USD
Chart
Data by YCharts
Industry
According to the World Health Organization (WHO), Coronavirus (CoV) is a family of viruses that cause illnesses ranging from common cold to lethal diseases such as the Middle East Respiratory Syndrome (MERS-CoV), Severe Acute Respiratory Syndrome (SARS-CoV) and a new strain of CoV named, novel coronavirus (nCoV). The virus is Zoonotic as it is transmitted from animals to humans, with the presence of many strains that have not yet infected humans. The infection manifests in the form of respiratory symptoms, cough, fever, shortness of breath and can take the form of pneumonia, severe acute respiratory syndrome, kidney failure and even death.
There is no definite cure for treatment or eradication of CoV, with treatment being limited to alleviation of symptoms, and providing support and care to patients. Scientists have been able to sequence the virus genetic code; spurring organizations around the world into action.
Diabetes is a silent killer which is slowly reaching epidemic proportions in developed as well as developing countries. The rise in obesity, sedentary lifestyles, poor dietary choices, stress and lack of exercise will see the number of incidences of Diabetes rise in the future. According to the International Diabetes Federation, the number of people living with diabetes will rise to 629 million by 2045, from 425 million adults (20-79 years) in 2017. In the U.S alone the people living with diabetes are set to increase from 58 million in 2017 to 67 million by 2045.
The increased awareness about the long-term complications caused by diabetes, along with the rise in co-morbidities such as cardiovascular, renal and neuropathic complications is set to propel the growth in the segment from $26.8 billion in 2016 to around $64 billion by 2026 according to a research by GlobalData. In spite of the market being dominated by generic drugs, such as metformin and similar drugs being in developmental stage, the market is projected to achieve a CAGR of 8.4% as per the same report.
Image Source: Company
Non-Invasive blood glucose monitoring offers a painless and more convenient alternative to monitoring glucose levels. According to a report by Coherent Market Insights, the global market for non-invasive blood glucose monitoring devices which were worth over US$ 5.1 million in 2017 will grow at a CAGR of 35.0% from 2018 – 2026. The ease and convenience of using the device, elimination of costly finger sticks and speedy transfer and sharing of data are some of the drivers of popularity of these devices, while the point of accuracy being lesser than conventional glucose monitoring devices may hamper its growth.
Company
Particle is a subsidiary of Know Labs, a Company developing non-invasive wearable blood glucose monitor UBAND that eliminates the need for fingersticks and micro needles. The Company’s cutting-edge technology can be applied to detect blood glucose and is also being tested to check for alcohol white blood cells, which could potentially serve as an advanced cancer detection system. Know Labs is also testing the device to check for alcohol levels in the body.
Image Source: Company
UBAND uses radio waves to detect changes in the body by using advanced machine learning and data science to detect molecules and their flow through the body. The Company is using its proprietary Bio-RFID sensor in combination with spectroscopy, that studies the interaction between matter and electromagnetic radiation to create a breakthrough solution in glucose monitoring that will also come with an iOS and Android App that will enable custom notifications on smartphones. The app will also be able to alert users to fluctuating levels or in cases of hyperglycemic or hypoglycemic.
In July 2020, the Company signed a research agreement with the Mayo Clinic to test and validate its Bio-RFID technology and intends to incorporate the technology into bands, mobile and bench-top models. The Company had earlier planned to submit an application to the FDA through the De Novo process in 2020 and launch the UBAND in early 2021, however the impact of COVID-19 pandemic has affected its plans of testing with third-party research organizations. However, the Company is replicating the tests internally to ensure positive results even in third-party testing.
Image Source: Company
In April 2020, the Company was granted a patent for its Bio-RFID technology, covering the platform nature of the Bio-RFID technology and health related diagnostics employing spectroscopy in the radio/microwave frequency band.
Phil Bosua, Know Labs CEO and inventor of the Bio-RFID technology, commented,
“We are extremely pleased and proud to obtain this patent. It is truly an invention which we believe can disrupt and revolutionize non-invasive human biomarker detection and medical diagnostics.”
Key Takeaways
Know Labs is gearing up for the commercial launch of the Particle bulb and has put in place a team equipped with necessary resources to ensure a smooth launch. The Company is also engaged in the in-house testing of the UBAND with an aim to miniaturize the technology and fine-tune its algorithm before third-party testing commences.
In March 2021, the Company closed a $14.2 million of financing through existing investors and insiders, to provide funds for product development, clinical testing and Uplisting to either NASDAQ or NYSE. The Company had earlier raised $5.7 Million in June 2020 through new and existing accredited investors.
Know Labs has initiated the process of uplisting on either NASDAQ or NYSE, which it believes will not only ensure a wider exposure and visibility to the Company but also enable it to attract institutional and retail investors. In addition, the move will also improve the liquidity of its stock and enhance long-term shareholder value. However, the process for uplisting is subject to approval and will only be granted if the Company is able to meet financial and liquidity requirements and has adequate provisions for corporate governance and disclosure requirements.
The capital raise is great news! The main obstacle facing KNWN was raising funds to continue as a going concern. Private offerings are always at a discount to the market. Given their present war chest, I have never felt more confident about their future prospects. The last time they did a raise the stock price doubled over the next two weeks. Consider this a wonderful buying opportunity.
RDHL sports a 1.8 billion market cap on 8 million in sales. Given the potential for sales with ATBPF 1.8 billion is a conservative #.
1.8 billion market cap is bubkis.
Naprosyn without the GI problems is a multi billion dollar market.Once approved ATBPF will sport a 2 billion dollar marketcap.30x's its present marketcap. Do the math folks.
yes hoping for good things out of EYES.
bullish on CYTK.
shorting.
massively oversold.
on the 15 minute chart.